PSNLHIGH SIGNALFINANCIAL10-K

PSNL shows concerning operational deterioration with declining revenue, substantially higher cash burn, and meaningfully expanded operating losses despite strengthened balance sheet position.

The company faces a challenging operational environment with revenue declining 17.7% while operating cash flow burn increased substantially, indicating potential execution or market demand issues. However, the strong balance sheet with increased cash reserves and equity provides financial cushion to navigate current headwinds.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

PSNL's financial position presents a mixed picture of balance sheet strength amid operational challenges. While cash and equivalents grew 35.9% to $124.2M and stockholders' equity expanded 28.7%, core operations deteriorated with revenue declining to $69.6M and operating losses widening to $88.1M. The substantially higher accounts receivable alongside revenue decline suggests potential collection or revenue recognition timing issues, while the meaningful increase in cash burn raises questions about operational efficiency and strategic execution.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
+99.1%
$8.1M→$16.2M

Receivables surged 99.1% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Operating Cash Flow
Cash Flow
-66%
-$45.1M→-$74.9M

Operating cash flow fell 66% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
+35.9%
$91.4M→$124.2M

Cash position surged 35.9% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+32%
$203.0M→$268.0M

Current assets grew 32% — improving short-term liquidity or inventory/receivables build.

Operating Income
P&L
-29%
-$68.3M→-$88.1M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Stockholders Equity
Balance Sheet
+28.7%
$203.0M→$261.2M

Equity base grew 28.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Liabilities
Balance Sheet
+27.3%
$31.1M→$39.6M

Current liabilities rose 27.3% — increased short-term obligations, watch current ratio.

Total Assets
Balance Sheet
+23.6%
$270.3M→$334.2M

Asset base grew 23.6% — expansion through organic growth, acquisitions, or capital deployment.

Revenue
P&L
-17.7%
$84.6M→$69.6M

Revenue softened 17.7% — monitor whether this is cyclical or structural.

SG&A Expense
P&L
+16%
$46.2M→$53.6M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
104,631,832 shares of common stock were issued and outstanding as of February 20, 2026.
Department of Veterans Affairs' Million Veteran Program ( VA MVP ), ModernaTX, Inc.
( Merck ), and other collaboration partners and customers; our belief that approval of personalized cancer therapies by the U.S.
We are pursuing a partner-centric strategy and have key relationships with Tempus, Myriad Genetics, Inc., Moderna, and Merck, among others.
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
Changes in health care policy could increase our costs, decrease our revenue, and impact sales of and reimbursement for our tests.
If we grow our business by developing additional in vitro diagnostic tests, we may be subject to reimbursement challenges.
If we cannot license rights to use necessary technologies on reasonable terms, we may not be able to commercialize new services.
Company Background Personalis develops, markets, and sells advanced cancer genomic testing services.
Testing Services For cancer patients NeXT Personal Dx NeXT Personal Dx is a tumor-informed liquid biopsy test for the detection of minimal residual disease ("MRD") and recurrence monitoring.
REMOVED
88,263,269 shares of common stock were issued and outstanding as of February 21, 2025.
Department of Veterans Affairs' Million Veteran Program, Natera, Inc., Moderna, Inc.
("Moderna"), and other collaboration partners and customers; our belief that approval of personalized cancer therapies by the U.S.
We are pursuing a partner-centric strategy and have key relationships with Tempus, Myriad Genetics, Inc, Moderna, and Merck Co., Inc., among others.
Our employees may engage in misconduct or other improper activities, such as noncompliance with regulatory standards and requirements, including the Foreign Corrupt Practices Act of 1977 and other anti-bribery laws, which could cause significant liability for us and harm our reputation.
When we grow our business by developing in vitro diagnostic tests, we may be subject to reimbursement challenges.
If we cannot license rights to use necessary technologies on reasonable terms, we may not be able to commercialize new services and products.
Company Background Personalis develops, markets, and sells advanced cancer genomic tests and services.
Products For pharmaceutical and biopharmaceutical companies NeXT Personal NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease ("MRD"), therapy response and recurrence monitoring, in solid tumor cancers.
For cancer patients NeXT Personal Dx NeXT Personal Dx is a tumor-informed liquid biopsy test for the detection of MRD.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →